搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 重組抗體
  4. BTLA Recombinant Monoclonal Antibody

BTLA Recombinant Monoclonal Antibody

  • 中文名稱：
    BTLA重組抗體
  • 貨號：
    CSB-RA773799MA1HU
  • 規(guī)格：
    ￥1320
  • 圖片：
    • The Binding Activity of Human BTLA with Anti-BTLA Recombinant Antibody
      Activity: Measured by its binding ability in a functional ELISA. Immobilized Human BTLA(CSB-MP773799HU1)at 2 μg/mL can bind Anti-BTLA recombinant antibody , the EC50 is 11.56-13.00 ng/mL.
    • Untransfected Jurkat cells surface (green line) and transfected Human BTLA Jurkat stable cells surface (red line) were stained with anti-BTLA antibody (2μg/1*106cells), washed and then followed by APC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.
    • Untransfected CHO-K1*106cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    CSB-RA773799MA1HU BTLA重組單克隆抗體是針對免疫檢查點分子BTLA（B and T lymphocyte attenuator）研發(fā)的高特異性檢測工具。該抗體經(jīng)ELISA和流式細(xì)胞術(shù)（FC）雙重驗證，在FC應(yīng)用中推薦使用1:20-1:200的稀釋范圍，展現(xiàn)優(yōu)異的結(jié)合能力和批次穩(wěn)定性。BTLA作為免疫球蛋白超家族成員，廣泛表達(dá)于T細(xì)胞、B細(xì)胞及抗原呈遞細(xì)胞表面，通過與HVEM受體相互作用傳遞抑制性信號，在維持免疫耐受和調(diào)控自身免疫反應(yīng)中發(fā)揮關(guān)鍵作用。本產(chǎn)品適用于體外研究BTLA介導(dǎo)的免疫調(diào)控機(jī)制，可精準(zhǔn)檢測免疫細(xì)胞亞群的BTLA表達(dá)水平，為腫瘤微環(huán)境中的免疫逃逸研究、自身免疫性疾病模型構(gòu)建以及免疫檢查點抑制劑的功能評估提供可靠工具。其流式細(xì)胞術(shù)檢測性能已通過標(biāo)準(zhǔn)免疫細(xì)胞系驗證，能夠有效支持免疫細(xì)胞表型分析、受體互作實驗以及相關(guān)信號通路研究，是探索免疫調(diào)節(jié)網(wǎng)絡(luò)和開發(fā)新型免疫療法的理想科研試劑。
  • Uniprot No.：
  • 基因名：
  • 別名：
    BTLA Recombinant Monoclonal Antibody
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    Recombinant Human BTLA protein
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標(biāo)記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 抗體亞型：
    Human IgG4
  • 純化方式：
    Affinity-chromatography
  • 克隆號：
    10A10
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用范圍：
    ELISA, FC
  • 推薦稀釋比：
    Application Recommended Dilution
    FC 1:20-1:200
  • Protocols：
  • 儲存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
  • 用途：
    For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點詳情

  • 功能：
    Inhibitory receptor on lymphocytes that negatively regulates antigen receptor signaling via PTPN6/SHP-1 and PTPN11/SHP-2. May interact in cis (on the same cell) or in trans (on other cells) with TNFRSF14. In cis interactions, appears to play an immune regulatory role inhibiting in trans interactions in naive T cells to maintain a resting state. In trans interactions, can predominate during adaptive immune response to provide survival signals to effector T cells.
  • 基因功能參考文獻(xiàn)：
    1. Data suggest that both HVEM and UL144 bind a common epitope of BTLA, whether engaged in trans or in cis; these studies were conducted in cell lines representing B-lymphocytes, T-lymphocytes, and natural killer cells. (HVEM = human herpes virus entry mediator; UL144 = membrane glycoprotein UL144 of Human herpesvirus 5; BTLA = human B- and T-lymphocyte attenuator) PMID: 29061848
    2. our data suggested that the BTLA/HVEM pathway contributes to peripheral T cell suppression in hepatocellular carcinoma patients PMID: 30116751
    3. data provide the first evidence that increased BTLA predicts poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL), and blockade of BTLA with other checkpoints may potentially represent a new strategy for immunotherapy of DLBCL. PMID: 29353075
    4. The genetic variants of rs76844316 in BTLA influence the susceptibility to severe chronic hepatitis B and might play a protective role against the progression of chronic hepatitis B. PMID: 29558758
    5. The impairment of Bregs and CD19+/BTLA+ cells could play an important pathogenic role in multiple sclerosis (MS). PMID: 27412504
    6. Our data portrays BTLA as a molecule with the singular ability to provide both costimulatory and coinhibitory signals to activated CD8(+) T cells, resulting in extended survival, improved tumor control, and the development of a functional recall response. PMID: 28754817
    7. results indicate that polymorphisms rs1982809 situated in 3' UTR nearby region of BTLA gene might be considered as low-penetrating risk factor for RCC, but results have to be confirmed in further studies PMID: 27234378
    8. The percentage of circulating BTLA+CD4+ lymphocytes was significantly higher in patients with severe community acquired pneumonia. PMID: 28164546
    9. Plasma concentrations of soluble BTLA were increased early in sepsis/septic shock and correlated to severity of disease. A baseline concentration >21ng/mL was associated with a poor prognosis. PMID: 28056053
    10. this study shows that in chronic hepatitis B virus patients, a subset of inefficient interferon-gamma producing antigen-specific CD8+ T cells recruited to the liver expressed high BTLA levels PMID: 27743606
    11. this study shows that BTLA expression is likely associated with positive rather than conventional negative regulation of CD11c antigen-presenting cell stimulatory capacity PMID: 27717503
    12. rs1982809 BTLA gene polymorphism is associated with mRNA expression level and variations in the BTLA gene might be considered as potentially low-penetrating chronic lymphocytic leukemia risk factor PMID: 27933341
    13. Study showed a decreased expression of BTLA in ocular Behcet's disease suggesting that it may be involved in the development and recurrence of this disease. PMID: 26841832
    14. BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine. PMID: 26277622
    15. our study confirms that CD200/BTLA deletions are recurrent genetic lesions in the biology of BCP-ALL PMID: 26137961
    16. Focal deletions of the BTLA were associated with B-cell precursor acute lymphoblastic leukemia. PMID: 25261097
    17. high BTLA expression levels in gastric cancer, identified by IHC, are an independent biomarker for the poor prognosis of patients with gastric cancer. PMID: 25334051
    18. Data indicate taht lung function and the expressions of B, T lymphocyte attenuator (BTLA) and Treg cells were lower in patients with rheumatism than those in normal controls. PMID: 24909289
    19. BTLA is a coreceptor that negatively regulates human Vgamma9Vdelta2 T-cell proliferation and has a role in immune escape for lymphoma cells PMID: 23692853
    20. BTLA and HVEM may have roles in graft rejection after kidney transplantation PMID: 23375291
    21. BTLA regulates human B cell responses and has implications for future development of therapies modulating B cells. PMID: 22903545
    22. The expression of BTLA has been observed on the surface of several kinds of cells within synovial tissues of RA patients, which indicates this signal might be involved in the regulation of local T cell activation and the pathogenesis of RA. PMID: 22691359
    23. These findings support role for BTLA and/or HVEM as potential, novel diagnostic markers of innate immune response/status and as therapeutic targets of sepsis. PMID: 22459947
    24. study described the expression and spatial distribution of HVEM and BTLA in rheumatoid arthritis synovial tissues, and results indicated that HVEM/BTLA may be involved in regulating the progress of joint inflammation PMID: 22179929
    25. BTLA-HVEM interactions impair minor histocompatibiility antigen-specific T cell functionality, providing a rationale for BTLA signaling blockade in post-stem cell transplantation. PMID: 22634623
    26. Added with PD-1 and Tim-3 blockades, BTLA blockade enhanced the expansion, proliferation, and cytokine production of NY-ESO-1-specific CD8(+) T cells. PMID: 22205715
    27. HVEM-BTLA cis complex provides intrinsic regulation in T cells serving as an interference mechanism silencing signals coming from the microenvironment. PMID: 21920726
    28. The results of a mutagenesis study of HVEM suggest that the CD160 binding region on HVEM was slightly different from, but overlapped with, the BTLA binding site. PMID: 21959263
    29. 590C single-nucleotide polymorphism of B- and T-lymphocyte attenuator was significantly associated with susceptibility to rheumatoid arthritis, but not to systemic lupus erythematosus or Sjogren's syndrome. PMID: 21403914
    30. BTLA expression on overall CD4(+) and CD8(+) T cells was progressively decreased in HIV-1 infection, which was directly correlated with disease progression and CD4(+) T-cell differentiation and activation PMID: 21592997
    31. In vitro blockade of the BTLA pathway augments allogeneic as well as cytomegalovirus-specific CD8-positive T cell proliferation, thereby enhancing the functional capacity of cytotoxic T lymphocytes in viral infections. PMID: 20693422
    32. BTLA gene polymorphisms may affect the sporadic breast cancer risk and prognosis in Chinese women in northeast of Heilongjiang Province PMID: 19585237
    33. Binding of HVEM to BTLA attenuates T cell activation, identifying HVEM/BTLA as a coinhibitory receptor pair. PMID: 15647361
    34. distinct herpesviruses target the HVEM-BTLA cosignaling pathway, suggesting the importance of this pathway in regulating T cell activation during host defenses. PMID: 16131544
    35. 2.8-A crystal structure of the BTLA-HVEM complex shows that BTLA binds the N-terminal cysteine-rich domain of HVEM and employs a unique binding surface PMID: 16169851
    36. BTLA is constitutively expressed on most CD4+ and CD8+ T cells and its expression progressively decreases upon T cell activation. PMID: 16643847
    37. Cross-linking of BTLA with mAb 7D7 suppressed T lymphocyte proliferation, downregulated the expression of T cell activation marker CD25, and inhibited the production of interferon (IFN)-gamma, interleukin (IL)-2, IL-4, and IL-10. PMID: 17257317
    38. BTLA is an inhibitory coreceptor of the B cell receptor (BCR) signaling pathway that attenuates B cell activation by targeting the downstream signaling molecules Syk and B cell linker protein (BLNK). PMID: 19155498
    39. this study did not find any genetic contribution of the BTLA gene to the development of T1D and SLE in Japanese population. PMID: 19207938
    40. results suggest that down-regulation of the BTLA-HVEM pathway may be involved in germinal center B-cell activation. PMID: 19762537
    41. the HVEM-BTLA cis-complex competitively inhibits HVEM activation by ligands expressed in the surrounding microenvironment, thus helping maintain T cells in the naive state. PMID: 19915044
    42. HVEM binds to B T lymphocyte attenuator (BTLA), an Ig family member, which inhibits T cell proliferation. PMID: 15568026

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Cell membrane; Single-pass type I membrane protein.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 21087

    OMIM: 607925

    KEGG: hsa:151888

    STRING: 9606.ENSP00000333919

    UniGene: Hs.445162